Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1569-8041
Volume Title
Publisher
Publisher DOI
Sponsorship
Cancer Research Uk (None)
Cancer Research UK (unknown)
Cancer Research UK (unknown)
Cancer Research UK (CB4140)